Is SL Science Holding Ltd (SLBT) a Buy, Sell, or Hold?
NASDAQ : SLBT
SL Science Holding Ltd — News
$3.885 USD
-$0.05 (-1.15%)
- Volume
- 26.76K
- Average Volume
- 731.51K
- Market Capitalization
- $30.76M
- P/E Ratio
- 0.00
- Dividend Yield
- 0.00%
- Price Target
- Year High
- $14.50
- Year Low
- $3.00
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $3.05
| Source | Headline |
|---|---|
|
SL Science Announces Successful Exhibition of Breakthrough Brain Cancer Therapy Research at the 2026 World Congress of Basic and Clinical Pharmacology
Joint presentation with Taipei Medical University, JY BioMed, and HeXun Biosciences highlighted the power of gamma delta (γδ) T cells in eliminating glioblastoma in preclinical studies. globenewswire.com - 2026-07-17 08:00:00 |
|
SL Science Holding Limited Submits Orphan Drug Designation Request to the U.S. FDA for GDT Cell Therapy Targeting Glioblastoma
Taipei, TAIWAN, July 10, 2026 (GLOBE NEWSWIRE) -- SL Science Holding Limited (“SL Science” or the “Company”) (Nasdaq: SLBT), a Taiwan-headquartered biomedical company specializing in developing innovative cellular and gene therapies, today announced that the Company has submitted an Orphan Drug Designation (ODD) request to the U.S. Food and Drug Administration (FDA) for its Gamma Delta T (GDT) cell therapy product, Vdelta2+ Gamma Delta T Cells, for the treatment of glioblastoma multiforme (GBM). The FDA's Office of Orphan Products Development (OOPD) has formally acknowledged receipt of the request and is proceeding with review on additional files about the product globenewswire.com - 2026-07-10 08:00:00 |
|
SL Science Holding, Alamos Gold And Other Big Stocks Moving Lower In Monday's Pre-Market Session
U.S. stock futures were mixed this morning, with the S&P 500 futures falling around 0.1% on Monday. benzinga.com - 2026-06-22 08:02:04 |
|
SL Science Holding Limited Reports Full Year 2025 Financial Results
Taipei, TAIWAN, June 18, 2026 (GLOBE NEWSWIRE) -- SL Science Holding Limited ("SL Science" or the "Company") (Nasdaq: SLBT), a Taiwan-headquartered biomedical company specializing in developing innovative cellular and gene therapies, today announced its financial results for the full year ended December 31, 2025. globenewswire.com - 2026-06-18 17:13:18 |
|
SL BIO Ltd. and Horizon Space Acquisition II Announce Closing of Business Combination and Listing on the Nasdaq Global Market
TAIPEI, Taiwan, June 12, 2026 (GLOBE NEWSWIRE) -- SL BIO Ltd. (“SL Bio” or the “Company”), a Taiwan-headquartered biomedical company specializing in developing innovative cellular and gene therapies, today announced the closing of its previously announced business combination with Horizon Space Acquisition II Corp. (Nasdaq: HSPT) (“Horizon Space”), a publicly traded special purpose acquisition company. globenewswire.com - 2026-06-12 14:51:00 |
